Abstract
Get full access to this article
View all access options for this article.
References
1.
Prasad
V
,
Makary
MA
FDA’s new plausible mechanism pathway . The New England Journal of Medicine ; 2025 . Available from: https://www.nejm.org/doi/full/10.1056/NEJMsb2512695 [Last accessed: December 4 , 2025
2.
Michaelides
M
,
Laich
Y
,
Wong
SC
et al. Gene therapy in children with AIPL1-associated severe retinal dystrophy: An open-label, first-in-human interventional study . The Lancet ; 2025 . Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02812-5/fulltext [Last accessed: December 4 , 2025
3.MeiraGTx Holdings . MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology . 2025 . Available from: https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-enters-strategic-collaboration-eli-lilly-and-company [Last accessed: December 4 , 2025
4.Regeneron Pharmaceuticals and Tessera Therapeutics . Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) . 2025 . Available from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-tessera-therapeutics-jointly-develop-tsra-196 [Last accessed: December 4 , 2025
5.U.S. Food and Drug Administration . FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury . 2025 . Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal [Last accessed:
December
4
].
6.Sarepta Therapeutics . Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information . 2025 . Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-fdas-approval-updated-elevidys-prescribing [Last accessed:
December
4
].
7.Novartis . Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) . 2025 . Available from: https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-itvisma-only-gene-replacement-therapy-children-two-years-and-older-teens-and-adults-spinal-muscular-atrophy-sma [Last accessed: December 1 , 2025
8.U.S. Food and Drug Administration . FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy . 2025 . Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy [Last accessed: December 2 , 2025
9.
Liu
A
. Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M . FierceBiotech ; 2025 . Available from: https://www.fiercepharma.com/pharma/novartis-scores-fda-approval-new-version-sma-gene-therapy-prices-259m [Last accessed: December 4 , 2025
10.uniQure . uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease . 2025 . Available from: https://uniqure.gcs-web.com/node/12406/pdf [Last accessed: December 4 , 2025
11.Solid Biosciences . Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia . 2025 . Available from: https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-receives-fda-rare-pediatric-disease [Last accessed: December 1 , 2025
12.AAVantgarde Bio . AAVantgarde Closes $141 Million Series B Financing . 2025 . Available from: https://www.aavantgarde.com/en/news/aavantgarde-closes-141-million-series-b-financing/ [Last accessed:
December
1
].